Reliable, reproducible organoids are vital for any large-scale screening program involving these powerful cell models. Now you can get the standardized organoids you need to scale up your research, obtain more robust results, and shorten your time to discovery.

Our products and services include:

• 3DReady organoid lines in an assay ready, vialled and cryopreserved ‘off the shelf format’ that are ideal for low- and high-throughput screening.
• Fully quality tested organoid line expansion, either from your own or from our portfolio.
• Bespoke PDO line generation and expansion from PDX (patient-derived xenograft) tissue.

Be one of the first to discover this game-changing organoid expansion solution

We are pleased to announce our collaboration with HUB Organoids (HUB), , a pioneer in the field of adult stem cell-derived organoids, to enable continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

Under this partnership, we will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types like heart and brain. The physiologically-relevant adult stem cell-derived organoids closely resembling human biology will be used to demonstrate proof of concept for an end-to-end automated workflow that encompasses instrumentation and software analysis.

The average cost of bringing a new drug to the clinic is around $1 billion, according to a study conducted by the London School of Economics in March 2020. This is partly due to the poorly representative models used for screening in the early stages of drug discovery. This has driven the search for more patient-centric models for early, accurate selection of lead candidates.

Patient-Derived Organoids (PDOs) grown in three dimensions represent a solution to this problem. Learn how these mini-organs can be used for screening “libraries” of potential therapeutics on our latest blog, a case study for assay-ready patient-derived organoids and high-throughput 3D imaging to advance drug discovery.

According to Biocompare, “one of the most overlooked pieces of equipment in any lab is the microplate reader. While they play an important role in generating data from a wide range of applications, few people give much thought to these lab workhorses despite the fact that their accuracy, precision, and repeatability are critical in generating reproducible results.”

In this article, Biocompare product reviewers share why the Molecular Devices SpectraMax M5 Multi-Mode Microplate Reader is one of the best on the market.

The increased complexities of high-throughput workflows within the lab can increase demands on researchers. As your lab’s needs expand, automation may be the solution for time-consuming manual processes. From increased walk-away time and throughput to reduced human error and improved lab safety, automation can keep routine work on track so that scientists can focus on more critical assay development challenges. Building an automation workcell for your lab can consist of different components, with each component offering its own advantage to the lab.

In this webinar, we will provide information to highlight how automation can help researchers move from time-consuming processes to efficient workflows.

Last week we attended SLAS in San Diego and were excited to showcase new industry collaborations, automated technology, and workflow innovations that span 3D biology, cell line development, and drug screening.

It was a great week full of tutorials, podium and poster presentations, product demonstrations, and more!

In addition to our microplate reader, high-content imaging, cell screening and clone screening solutions, we also offer the ability to customize and automate your specific workflow - as shown by our Organoid Innovation Center.

Ready to reach your full potential? Click here to see what life is like at Molecular Devices.